Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
14 evidence topics · 11 sources
Clinical diagnosis of the primary ocular tumor
Guideline recommendations on ocular imaging and biopsy of the primary tumor
“UM diagnosis is based on clinical examination by ophthalmoscopy, fundus photography and conventional ocular ultrasound (US) in patients presenting with blurred vision or other visual symptoms; however, 13%-30% are diagnosed during routine eye examinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biopsy is not mandatory for typical UM diagnosis, which is well characterised by ophthalmoscopy, fundus photography and conventional ocular US [II, D].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A biopsy is recommended if the clinical diagnosis is uncertain and if it has been discussed with the patient due to the potential risks of the procedure and the uncertainty of a conclusive result [II, A].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Staging and screening for distant metastases at diagnosis
“UM should be staged according to the eighth edition of the AJCC Cancer Staging Manual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should be screened for distant metastases [liver US or MRI with diffusion-weighted sequences, supplemented by positron emission tomography (PET)–computed tomography (CT) or thoraco-abdomino-pelvic CT for extrahepatic extension].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecular prognostic testing of the primary tumor: methods and risk groups
“The most commonly used prognostic tests are FISH, multiplex ligation-dependent probe amplification, microsatellite analysis, single-nucleotide polymorphism array, array comparative genomic hybridisation, targeted NGS and a 12-gene PCR assay based on gene expression profiling (GEP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A low risk of metastasis is associated with tumours that have normal chromosomes 3 and 8; these tumours often display 6p gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Late but infrequent metastatic spread is associated with normal chromosome 3, one or more extra copies of (partial) chromosome 8, GEP class 1 status and with PRAME expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A high risk of metastasis is associated with loss of one copy of chromosome 3 or isodisomy of this chromosome, polysomy of chromosome 8q, a GEP class 2 profile and inactivating mutations or deletions of the BAP1 gene located on chromosome 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gene expression profile class 1 and class 2: prospective multicenter validation
“The GEP assay successfully classified 446/459 (97.2%) cases. The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Metastasis was detected in 3 (1.1%) class 1 cases and 44 (25.9%) class 2 cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using multivariate Cox modeling, GEP class had a stronger independent association with metastasis than any other prognostic factor (P<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommended molecular work-up of primary and metastatic tumors
“If sufficient tumour material is available, the molecular work-up of primary UM could include copy number assessment in chromosomes 3, 6 and 8, GEP, mutational status of BAP1, SF3B1, EIF1AX, and immunohistochemistry for BAP1 and PRAME expression [III, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assessment of mutational status of GNAQ, GNA11, SF3B1 and MBD4 may be recommended in the metastatic setting as results may impact treatment decisions [IV, C].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surveillance imaging of the liver after treatment of the primary tumor
“There is no prospective evidence that imaging surveillance impacts the outcomes of patients with UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver function tests have a low sensitivity and do not help detect early metastasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hepatic US has a sensitivity of 96% in detecting liver metastasis from UM but the positive predictive value (PPV) is only 45%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gadolinium-enhanced liver MRI with diffusion-weighted sequences has demonstrated sensitivity of nearly 100% and specificity of 80%-99%, with a better ability to detect small lesions compared with US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genetic and clinical factors should be used to guide surveillance, as there is no standard approach to detecting metastases in patients with UM [III, A].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sensitivity of hepatic ultrasonography and MRI for surveillance
“Hepatic ultrasonography and magnetic resonance imaging as surveillance methods have a sensitivity of 95-100% and 83-100%, respectively, to detect metastases without radiation hazard according to prevailing evidence, but computed tomography is necessary for staging.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver function test screening for metastasis, COMS trials
“Based on all patients with reported metastasis, the sensitivity, specificity, positive predictive value and negative predictive value associated with at least one abnormal LFT before first diagnosis of metastasis at any site was 14.7%, 92.3%, 45.7% and 71.0%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Detection of metastases by screening ultrasonography and liver function tests
“Metastases were diagnosed in 74% of patients (95% confidence interval [95% CI], 59-86) at screening and in 26% (95% CI, 14-41) when the patient consulted a physician because of symptoms that developed before the next scheduled visit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“US was diagnostic in 78% (95% CI, 64-89), at least 1 LFT test was abnormal in 70% of patients (95% CI, 54-82), and a chest X-ray was abnormal in 2% of patients (95% CI, 0-12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Staging imaging and biopsy confirmation of metastatic disease
“Staging of metastatic disease is based on total body CT scan and liver MRI; brain imaging is not required in the absence of central nervous system symptoms; the usefulness of fluorodeoxyglucose (FDG)–PET–CT is still debated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote